TY - JOUR
T1 - Immunoliposomal delivery of 213Bi for α-emitter targeting of metastatic breast cancer
AU - Lingappa, Mohanambe
AU - Song, Hong
AU - Thompson, Sarah
AU - Bruchertseifer, Frank
AU - Morgenstern, Alfred
AU - Sgouros, George
PY - 2010/9/1
Y1 - 2010/9/1
N2 - Current treatment for late-stage metastatic breast cancer is largely palliative. α-Particles are highly potent, short-range radiation emissions capable of sterilizing individual cells with one to three traversals of the cell nucleus. The α-emitter, 213Bi (T1/2 = 45.6 min), was conjugated to a 100-nm diameter liposomal-CHX-A″-DTPA construct, upon which the rat HER2/neu reactive antibody, 7.16.4, was grafted. A conjugation time of 10 minutes was achieved giving a specific activity corresponding to 0.1 213Bi atom per liposome; stability in vitro and in vivo was confirmed. Efficacy in a rat/neu transgenic mouse model of metastatic mammary carcinoma was investigated. Three days after left cardiac ventricular injection of 105 rat HER-2/neu-expressing syngeneic tumor cells, macrophage-depleted Neu-N mice were treated by i.v. injection with (a) 19.2 MBq (520 μCi) of liposome-CHX-A″-DTPA-213Bi, (b) 19.2 MBq of liposome-CHX-A″-DTPA-213Bi-7.16.4, (c) 4.44 MBq (120 μCi) of 213Bi-7.16.4, and (d) cold (nonradioactive) liposome-CHX-A″-DTPA-7.16.4 as control. Treatment with (a) increased median survival time to 34 days compared with 29 days for the untreated controls (P = 0.013) and 27 days for treated cold controls. Treatment with the radiolabeled antibody-conjugated liposome (b) increased median survival time to 38 days (P = 0.0002 relative to untreated controls). The radiolabeled antibody-treated group (c) gave a median survival of 39 days, which was similar to that for the radiolabeled antibody-conjugated liposome-treated group (P = 0.5). We have shown that the 213Bi radiolabeled immunoliposomes are effective in treating early-stage micrometastases, giving median survival times similar to those obtained with antibody-mediated delivery of 213Bi in this animal model.
AB - Current treatment for late-stage metastatic breast cancer is largely palliative. α-Particles are highly potent, short-range radiation emissions capable of sterilizing individual cells with one to three traversals of the cell nucleus. The α-emitter, 213Bi (T1/2 = 45.6 min), was conjugated to a 100-nm diameter liposomal-CHX-A″-DTPA construct, upon which the rat HER2/neu reactive antibody, 7.16.4, was grafted. A conjugation time of 10 minutes was achieved giving a specific activity corresponding to 0.1 213Bi atom per liposome; stability in vitro and in vivo was confirmed. Efficacy in a rat/neu transgenic mouse model of metastatic mammary carcinoma was investigated. Three days after left cardiac ventricular injection of 105 rat HER-2/neu-expressing syngeneic tumor cells, macrophage-depleted Neu-N mice were treated by i.v. injection with (a) 19.2 MBq (520 μCi) of liposome-CHX-A″-DTPA-213Bi, (b) 19.2 MBq of liposome-CHX-A″-DTPA-213Bi-7.16.4, (c) 4.44 MBq (120 μCi) of 213Bi-7.16.4, and (d) cold (nonradioactive) liposome-CHX-A″-DTPA-7.16.4 as control. Treatment with (a) increased median survival time to 34 days compared with 29 days for the untreated controls (P = 0.013) and 27 days for treated cold controls. Treatment with the radiolabeled antibody-conjugated liposome (b) increased median survival time to 38 days (P = 0.0002 relative to untreated controls). The radiolabeled antibody-treated group (c) gave a median survival of 39 days, which was similar to that for the radiolabeled antibody-conjugated liposome-treated group (P = 0.5). We have shown that the 213Bi radiolabeled immunoliposomes are effective in treating early-stage micrometastases, giving median survival times similar to those obtained with antibody-mediated delivery of 213Bi in this animal model.
UR - http://www.scopus.com/inward/record.url?scp=77956279807&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77956279807&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-09-4548
DO - 10.1158/0008-5472.CAN-09-4548
M3 - Article
C2 - 20651254
AN - SCOPUS:77956279807
SN - 0008-5472
VL - 70
SP - 6815
EP - 6823
JO - Cancer Research
JF - Cancer Research
IS - 17
ER -